CNC

Business profile & competitive position

Centene Corp. (ticker: CNC) is classified in the Healthcare sector, specifically the Medical - Healthcare Plans industry. According to its most recent 10-K, it is the nation’s largest managed care company focused on underserved populations, delivering Medicaid, Medicare Advantage, Prescription Drug Plans, stand-alone PDP products, and commercial plans through the Health Insurance Marketplace. It operates through local brands backed by national infrastructure, and it also connects members to non-medical supports such as food, housing, utilities, and transportation.

The company’s scale is material: as of December 31, 2025, total membership was 27.6 million, including 12.5 million Medicaid members, 5.5 million Marketplace members, and 8.1 million stand-alone PDP members. The filing also identifies Centene as the largest Medicaid insurer, the largest Marketplace insurer, and the largest stand-alone PDP provider in the United States.

That scale, however, does not currently translate into positive profitability. The reported net margin is -2.6% and ROE is -24.0%. Those figures imply that Centene’s government-program footprint and membership density give it market presence, but not a margin moat strong enough to produce current earnings. Negative returns on equity suggest capital is not generating positive net income at this stage, so “competitive position” here is better measured in enrollment share and program access than in bottom-line returns.

Financial posture

Centene’s market cap stands at $33.9 billion. Its trailing price-to-earnings ratio is -6.6, which reflects the fact that the company is reporting net losses rather than any premium or discount in conventional P/E terms. The net margin of -2.6% and ROE of -24.0% reinforce that earnings-based valuation is not the right lens right now.

A more useful counterpoint is cash flow. The 10-K states 2025 operating cash flow of $5.1 billion on $194.8 billion in revenue. That suggests the business still generates cash from operations despite net losses, which can be important for a managed-care model where premium timing, medical reserves, and reimbursement flows create accounting volatility.

The stock’s current price is $68.63, with a 50-day EMA of $65.37, meaning the share price sits above its near-term trend. RSI is 60.1, neither overbought nor oversold. The beta of 1.13 indicates the stock has been slightly more volatile than the broad market, consistent with a policy-sensitive healthcare name. No debt figure was included in the available snapshot, so any leverage assessment should wait for the full balance sheet rather than be inferred.

Strategic priorities & outlook

Centene’s own 10-K filing outlines a handful of clear near-term priorities:

• Medicare-Medicaid overlap: Continue refining the Medicare footprint so it overlaps more closely with Medicaid operations, and expand Dual Eligible Special Needs Plans (D-SNP) as a long-term growth driver.
• Regulatory alignment through 2030: Maintain an enterprise focus on D-SNP integrated products aligned with CMS requirements taking effect through 2030.
• Policy advocacy: Advocate for policies and legislation aimed at preserving affordable Medicaid and Marketplace coverage, plus cost-effective, high-quality PDP care.
• Marketplace repricing and expansion: Implement 2026 corrective Marketplace pricing actions in states covering 95% of Marketplace membership, and expand Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states.

Operationally, the 2025 revenue mix was 57% Medicaid, 21% Commercial, 19% Medicare, and 3% Other. Medicaid remains the dominant profit-and-loss driver, so changes to state or federal Medicaid policy will likely have outsized impact. The company also disclosed that in December 2025 it signed a definitive agreement to divest the remaining Magellan Health businesses, which appears to be part of a broader simplification effort.

Macro & geopolitical exposure

As a Medical - Healthcare Plans company, Centene is exposed to the regulatory and reimbursement environment rather than direct commodity or foreign-exchange risk. The most relevant macro drivers include federal Medicare and Medicaid policy, CMS rate-setting actions, Affordable Care Act changes, state Medicaid expansion or contraction, Medicare Advantage star-rating rules, and prescription-drug pricing legislation.

Reimbursement pressure, changes to eligibility rules, and shifts in exchange-market subsidies can move revenue faster than costs can adjust. Medical-cost inflation, hospital and physician contract pricing, and pharmacy spending also matter because premium revenue is set in advance while medical claims play out over the contract year. In short, the stock is policy-rate-and-cost sensitive; its macro playbook is closer to Washington and state-capital budget decisions than to oil prices or global trade lanes.

Recent developments

Headlines around the name in mid-October 2026 include:

• October 19, 2026 — prnewswire.com: “CENTENE CORPORATION TO HOST 2026 THIRD QUARTER FINANCIAL RESULTS EARNINGS CALL.” The company scheduled its Q3 2026 call ahead of an earnings release date of October 27, 2026, before the market open.
• October 19, 2026 — 247wallst.com: “4.6 Million Americans Leave Health Insurance Market in Biggest Exodus in a Decade — and Those Staying Face a 15% Rate Hike.” For Centene, the largest Marketplace insurer, enrollment and pricing trends on the exchange are directly relevant to the 21% of revenue classified as Commercial and to the 5.5 million Marketplace members reported at year-end 2025.
• October 16, 2026 — prnewswire.com: “Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma.” This points to continued state-market benefit design activity, which can affect member acquisition and retention.
• October 14, 2026 — zacks.com: “Centene's Gold Card Push Could Ease Costs - But Will Savings Follow?” The article flags a New Mexico initiative; if the model is expanded, it could affect medical-cost management, though the headline itself questions whether realized savings will materialize.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Centene has beaten the listed consensus estimate seven times, for an 88% beat rate. The average earnings surprise across those quarters is 63.1%, which is unusually large and reflects both low estimate bars and significant earnings volatility.

Despite the strong beat history, next-day price reactions have been inconsistent. Among the most recent four quarters:

• On July 28, 2026, actual EPS was $2.51 versus an estimate of $1.09 (130.3% surprise). The stock fell 3.27% the next day and drifted only 0.25% over the following five sessions.
• On April 28, 2026, actual EPS was $3.37 versus an estimate of $2.23 (51.1% surprise). The stock rose 8.9% the next day and added 6.88% over the following five sessions.
• On February 6, 2026, actual EPS was -$1.19 versus an estimate of -$1.22007 (2.5% surprise). The stock slipped 1.09% the next day but drifted 5.51% higher over the following five sessions.
• On October 29, 2025, actual EPS was $0.50 versus an estimate of -$0.14475 (445.4% surprise). The stock dropped 6.21% the next day and was down 1.34% over the following five sessions.

Averaging all eight quarters, the five-trading-day post-earnings drift is 2.83%, classified as an upward drift. That suggests the market has tended to revise its view positively after the initial noise, even when the first-day reaction is negative. The unofficial consensus for the upcoming October 27, 2026 report is $0.09564 per share.

If you want to go deeper than the headline numbers and news flow, the next step is to review the full institutional verdict on CNC, including updated sell-side models, insider activity, and options market positioning around the October 27 report.